Systemic Overexpression of IL-10 Induces CD4+CD25+ Cell Populations In Vivo and Ameliorates Type 1 Diabetes in Nonobese Diabetic Mice in a Dose-Dependent Fashion
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Early systemic treatment of nonobese diabetic mice with high doses of recombinant adeno-associated virus (rAAV) vector expressing murine IL-10 prevents type 1 diabetes. To determine the therapeutic parameters and immunological mechanisms underlying this observation, female nonobese diabetic mice at 4, 8, and 12 wk of age were given a single i.m. injection of rAAV-murine IL-10 (104, 106, 108, and 109 infectious units (IU)), rAAV-vector expressing truncated murine IL-10 fragment (109 IU), or saline. Transduction with rAAV-IL-10 at 109 IU completely prevented diabetes in all animals injected at all time points, including, surprisingly, 12-wk-old animals. Treatment with 108 IU provided no protection in the 12-wk-old injected mice, partial prevention in 8-wk-old mice, and full protection in all animals injected at 4 wk of age. All other treatment groups developed diabetes at a similar rate. The rAAV-IL-10 therapy attenuated pancreatic insulitis, decreased MHC II expression on CD11b+ cells, increased the population of CD11b+ cells, and modulated insulin autoantibody production. Interestingly, rAAV-IL-10 therapy dramatically increased the percentage of CD4+CD25+ regulatory T cells. Adoptive transfer studies suggest that rAAV-IL-10 treatment alters the capacity of splenocytes to impart type 1 diabetes in recipient animals. This study indicates the potential for immunomodulatory gene therapy to prevent autoimmune diseases, including type 1 diabetes, and implicates IL-10 as a molecule capable of increasing the percentages of regulatory cells in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737 · cited 4×
“IL-10 was created by sitedirected mutagenesis, creating a truncated IL-10 peptide by introducing a stop codon 33 bp downstream of the start codon (6).”
BackgroundMethodInfluentialType 1 diabetes: new perspectives on disease pathogenesis and treatment
Atkinson, M. A., & Eisenbarth, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05415-0 · Cited by 1,491
Self-citationThe NOD mouse model of type 1 diabetes: As good as it gets?
Atkinson, M. A., & Leiter, E. H. (1999) · Nature Medicine · doi:10.1038/9442 · Cited by 588 · cited 1×
“, proteins, Abs, dendritic cells, and cytokines) to induce Th2 responses; all with varying degrees of success with respect to disease prevention (5).”
BackgroundSelf-citation
Cited by
Herman, A. E., Freeman, G. J., Mathis, D., & Benoist, C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040179 · Cited by 450
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation
Shoda, L. K. M., Young, D. L., Ramanujan, S., Whiting, C. C., Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Mathis, D., Rossini, A. A., Campbell, S. E., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.08.002 · Cited by 317
Self-citationHata, H., Sakaguchi, N., Yoshitomi, H., Iwakura, Y., Sekikawa, K., Azuma, Y., Kanai, C., Moriizumi, E., Nomura, T., Nakamura, T., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421795 · Cited by 304
Th17 Cells in Immunity and Autoimmunity
Bedoya, S. K., Lam, B., Lau, K., & Larkin, J. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/986789 · Cited by 282
Jinushi, M., Takehara, T., Tatsumi, T., Kanto, T., Miyagi, T., Suzuki, T., Kanazawa, Y., Hiramatsu, N., & Hayashi, N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6072 · Cited by 228
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“NOD mice newly diagnosed with diabetes also benefit from muscle-directed AAV IL-10 therapy given in combination with islet cell transplants with increases in regulatory T cells, reduced lymphocyte infiltration, and induced antioxidant enzymes in islet grafts (Goudy et al. 2003).”
BackgroundNAYAK, S., CAO, O., HOFFMAN, B. E., COOPER, M., ZHOU, S., ATKINSON, M. A., & HERZOG, R. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03548.x · Cited by 66
Self-citationUpdate on islet cell transplantation
Verhoeff, K., Marfil-Garza, B. A., & Shapiro, A. M. J. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000891 · Cited by 29
Immunological Effects of Probiotics and their Significance to Human Health
Gill, H. S., Grover, S., Batish, V. K., & Gill, P. (2009) · Prebiotics and Probiotics Science and Technology · doi:10.1007/978-0-387-79058-9_23 · Cited by 13
Metadata
- Authors
- Goudy, K. S., Burkhardt, B. R., Wasserfall, C., Song, S., Campbell-Thompson, M. L., Brusko, T., Powers, M. A., Clare-Salzler, M. J., Sobel, E. S., Ellis, T. M., Flotte, T. R., & Atkinson, M. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-09-01
- Volume
- 171
- Issue
- 5
- Pages
- 2270-2278
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2109410335
- Cited by
- 131
- References
- 3
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.